Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for reducing ICU-acquired infections in septic patients with sepsis-induced immunosuppression
2014-001894-15Phase 3Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and septic shock comparing Sargramostim with Placebo (2 arms). Started Jun 2015; status: active.
02
Drugs
sargramostim
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2014-001894-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001894-15.